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Summary
In 1993, two groups showed that X-linked agamma-
globulinemia (XLA) was due to mutations in a tyrosine
kinase now called Btk. Most laboratories have been able
to detect mutations in Btk in 80%–90% of males with
presumed XLA. The remaining patients may have mu-
tations in Btk that are difficult to identify, or they may
have defects that are phenotypically similar to XLA but
genotypically different. We analyzed 101 families in
which affected males were diagnosed as having XLA.
Mutations in Btk were identified in 38 of 40 families
with more than one affected family member and in 56
of 61 families with sporadic disease. Excluding the pa-
tients in whom the marked decrease in B cell numbers
characteristic of XLA could not be confirmed by im-
munofluorescence studies, mutations in Btk were iden-
tified in 43 of 46 patients with presumed sporadic XLA.
Two of the three remaining patients had defects in other
genes required for normal B cell development, and the
third patient was unlikely to have XLA, on the basis of
results of extensive Btk analysis. Our techniques were
unable to identify a mutation in Btk in one male with
both a family history and laboratory findings suggestive
of XLA. DNA samples from 41 of 49 of the mothers of
males with sporadic disease and proven mutations in
Btk were positive for the mutation found in their son.
In the other 8 families, the mutation appeared to arise
in the maternal germ line. In 20 families, haplotype anal-
ysis showed that the new mutation originated in the
maternal grandfather or great-grandfather. These studies
indicate that 90%–95% of males with presumed XLA
have mutations in Btk. The other patients are likely to
have defects in other genes.
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Introduction
X-linked agammaglobulinemia (XLA [MIM 300300]) is
a fully penetrant X-linked recessive disorder character-
ized by the early onset of bacterial infection, profound
hypogammaglobulinemia, and a marked decrease in the
number of B lymphocytes, the precursors of antibody
producing cells (Conley et al. 1994b; Ochs and Smith
1996). Although most affected males are recognized to
have immunodeficiency in the first few years of life, di-
agnosis may be delayed, particularly in atypical or spo-
radic cases (Conley and Puck 1988; Vorechkovsky et al.
1993; Kornfeld et al. 1996). As would be expected for
any X-linked disorder that is lethal without medical in-
tervention, 30%–50% of patients with the clinical and
laboratory features of XLA have no family history of
disease (Haldane 1935; Lederman and Winkelstein
1985). Accurate diagnosis and genetic counseling are
further complicated by the fact that there are autosomal
recessive disorders that result in a phenotype indistin-
guishable from XLA (Hoffman et al. 1977; Conley and
Sweinberg 1992; Yel et al. 1996; Minegishi et al. 1998).
Carrier testing can confirm the diagnosis of XLA in
patients with atypical cases or when there is no family
history of disease (Conley et al. 1986; Fearon et al. 1987;
Conley and Puck 1988; Allen et al. 1994). Because the
defective gene product is intrinsic to the B cell lineage
and is not transportable between cells, B cell precursors
from obligate carriers that have the mutant X chro-
mosome as the active X do not mature into B cells. As
a result, B cells, but not other hematopoietic cell lineages
from these women, demonstrate a nonrandom pattern
of X chromosome inactivation (Conley et al. 1986; Fea-
ron et al. 1987; Conley and Puck 1988; Allen et al.
1994). However, this approach is labor intensive, and a
random pattern of X chromosome inactivation in B cells
from the mother of a patient does not rule out the pos-
sibility of a new mutation in the maternal germ line.
In 1993, two groups demonstrated that XLA was due
to mutations in Btk, a cytoplasmic tyrosine kinase that
is expressed throughout B cell and myeloid differentia-
tion (Tsukada et al. 1993; Vetrie et al. 1993). In addition
to its catalytic domain, Btk contains several protein-pro-
tein interaction domains, including a pleckstrin homol-
ogy (PH) domain and SH2 and SH3 domains (Tsukada
Conley et al.: Sporadic X-Linked Agammaglobulinemia 1035
et al. 1993; Vetrie et al. 1993; Rawlings and Witte 1995).
Although the mechanisms by which defects in Btk result
in a failure of B cell development have not yet been
identified, comparison to other cytoplasmic tyrosine ki-
nases suggests that this enzyme is involved in control of
cell proliferation or differentiation (Rawlings and Witte
1995).
The gene encoding Btk consists of 19 exons spread
over 37 kb of DNA (Hagemann et al. 1994; Ohta et al.
1994; Rohrer et al. 1994; Sideras et al. 1994). Over 200
mutations have been identified by means of Southern
blot analysis, cDNA sequencing, and genomic screening
(Vihinen et al. 1996). Gross deletions or insertions de-
tectable by Southern blot analysis constitute ∼5% of the
mutations; the remaining mutations are scattered
throughout the gene and are highly diverse. They include
single–base-pair substitutions that cause amino acid sub-
stitutions, premature stop codons and splice defects, and
small insertions and deletions that result in frameshift
mutations. Most laboratories that have screened for mu-
tations in Btk have identified mutations in 80%–90%
of the patients evaluated (Bradley et al. 1994; Conley et
al. 1994a; Hagemann et al. 1994; Hashimoto et al.
1996). It is not clear whether the remaining 10%–20%
of patients have mutations in Btk that are not easily
detected or whether they have disorders that are phe-
notypically similar to XLA but are caused by different
gene defects.
To facilitate genetic counseling for families in which
a male has the clinical features of XLA but no family
history of disease, we screened genomic DNA, using
SSCP, for mutations in Btk. If a mutation in Btk was
not identified, Southern blot analysis was used to identify
gross alterations in the gene, cDNA was screened by
SSCP, and Btk protein was evaluated by western blot
analysis when possible. We also screened for mutations
in other genes that might affect B cell development.
When a mutation in Btk was identified, genomic DNA
from the patient’s maternal ancestors was examined to
determine the source of new mutations.
Material and Methods
Patients
Twenty-one of the patients included in this study have
received care in our clinics. The remaining families were
referred for molecular diagnosis by physicians or genetic
counselors from 37 different institutions. When possible,
a fresh blood sample from an affected patient was an-
alyzed by immunofluorescence staining with antibody to
CD19, to confirm the characteristic decrease in B cell
numbers (Conley 1985). In some cases, it was not pos-
sible to confirm the diagnosis, and only DNA samples
from the patient (12 families) or a female relative (eight
families) were available. Members of 108 families were
screened for mutations in Btk. Six families in whom Btk
mutations were not identified were excluded from final
analysis in this study because, although the proband had
markedly reduced B cell numbers, the patient was not
presumed to have XLA. In four of these families, the
proband was a female, and in the remaining two, the
affected child had intrauterine growth retardation and
other morphologic defects atypical of XLA. The DNA
sample from one patient was partially degraded and was
not further analyzed. Thus, 101 families were included
in the final analysis. This study was reviewed by the St.
Jude Children’s Research Hospital Institutional Review
Board, and informed consent was obtained from all
subjects.
Mutation Detection
Genomic DNA was obtained from whole blood lysis
or from mitogen-stimulated T cells from patients and
family members. SSCP analysis was performed as de-
scribed (Conley et al. 1994a) except that the following
primer pair (sense: GTGCCTTTAACCTCTGTGCT and
antisense: TACCCATGTTTCATACTGTG) was substi-
tuted for the exon 16 primer pair. The promoter region
(300 bp 5′ to the transcriptional start site) was analyzed
with primers (sense: GAGGATAGCTTGATGACC and
antisense: GGCCCTGGAGACATATTC) and the polyA
tail was analyzed with the primers (sense: CCGA-
ATTTGGCAAGAAT and antisense: TCGAGTTCT-
CAGTGTAGG). All assays were run at 4C. Exons dem-
onstrating altered migration were cloned from two
separate PCR reactions and sequenced. Family members
were then screened, by SSCP, for the same mutation.
Linkage Analysis
Short tandem repeats near the XLA locus at Xq22,
DXS178CA (Allen and Belmont 1992), DXS101 (Allen
and Belmont 1993), DXS6799, DXS6797, and
DXS6804 (Research Genetics) were used for linkage
analysis and to assign haplotypes.
Results
We have used SSCP to screen for mutations in Btk in
members of 101 families in which an immunodeficient
male was thought to have XLA. Thirty of these families
included affected cousins or uncles. In 10 families, two
or more brothers, but no additional family members,
had the clinical and laboratory features of XLA. The
patients in the remaining 61 families were presumed to
have sporadic XLA. Eighty-three different mutations in
Btk were identified in members of 94 families. Seventy-
six of the 83 mutations resulted in an abnormal migra-
tion of PCR products from a single exon with its flanking
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splice sites. Four additional mutations resulted in the
consistent failure to amplify one or more exons by PCR.
Southern blot analysis demonstrated gross deletions in
the Btk gene in the four samples that could not be com-
pletely analyzed by SSCP (patients 0703, 0850, 2430,
and 2433) and insertions in three additional samples
(patients 0060, 0540, and 1107). Of the 83 unique mu-
tations included in this study, 43 have been described
elsewhere by our laboratory (Conley et al. 1994a; Con-
ley and Rohrer 1995; Farrar et al. 1996; Rohrer and
Conley 1998), 5 have been reported by other groups
(Bradley et al. 1994; Hagemann et al. 1994; Jin et al.
1995; Hashimoto et al. 1996; Kornfeld et al. 1996), and
35 have not been previously described.
Ten mutations were found in more than one family,
1 of these occurred in three families, and the other 9
were found in two families. To determine whether these
10 mutations were due to independent mutational events
or shared ancestry, the haplotype bearing the mutation
was analyzed by use of the short tandem repeats linked
to Btk at Xq22, or the source of the mutation was iden-
tified in one of the families. These studies showed that
two of the families, one with a known family history of
XLA (patient 0030) and the other thought to have spo-
radic XLA (patient 0025), were distantly related, as re-
ported elsewhere (Rohrer and Conley 1998). The other
nine mutations occurred independently, as shown by
haplotype analysis (patients 0200 and 0300, 0770 and
0771, 1030 and 1031, 1110 and 1111, 1500 and 1600,
and 2000 and 2017) or identification of the source of
the mutation in one of the families (patients 0310, 1426,
1470, and 2273). Four of the sites involved in recurrent
mutations were CpG dinucleotides at codons 13, 255,
288, and 520.
The 93 independently derived mutations included 62
single–base-pair substitutions that resulted in amino acid
substitutions (28 mutations), premature stop codons (21
mutations), splice defects (11 mutations), a transcrip-
tional regulatory defect (1 mutation), and a defect in the
start codon (1 mutation). An additional 20 mutations
were small insertions or deletions. Most of these mu-
tations occurred in the coding regions and caused a
frameshift with a secondary premature stop codon; how-
ever, three mutations (patients 0620, 1426, and 1427),
were 3-bp deletions that would be expected to result in
a single amino acid deletion. Four mutations were
slightly more complex and resulted in the combination
of small insertions with small deletions. DNA from pa-
tient 2390 demonstrated a 16-bp deletion of nucleotides
2016–2032 of the coding region, coupled with a 4-bp
TTGC insertion. The predicted consequence of this mu-
tation would be an in-frame deletion of amino acids at
codon 629–633 with the insertion of a cysteine. Two of
the insertion/deletion combinations, in patients 0870
and 1100, would be expected to cause frameshifts. The
fourth insertion/deletion, in patient 1120, occurred at
the 10 position of the splice-acceptor site in the 10th
intron and consisted of a G deletion coupled to an 11-
bp insertion (AGGGGAAAACT). Because the insertion
occurred immediately 3′ to a cytosine, the new sequence
created a splice-acceptor site. Analysis of cDNA from
this patient demonstrated the use of cryptic splice sites
and exon skipping. The remaining seven mutations were
gross deletions or insertions.
As reported elsewhere (Conley et al. 1994b; de Weers
et al. 1994; Ohta et al. 1994; Jin et al. 1995), there was
no clear phenotype/genotype correlation in patients with
mutations in Btk, indicating that the specific mutation
in Btk is only one of the factors that influences the se-
verity of disease. The age at diagnosis, the severity of
the infections prior to diagnosis, and the incidence of
complications after diagnosis were highly variable even
among patients with premature stop codons and an ab-
sence of Btk transcript and protein. The most consistent
feature, found in all of the patients analyzed, was a
marked reduction in the number of B cells.
Mutations in Btk were identified in 38 of 40 families
that included more than one individual with presumed
XLA. One of the families in whom we did not find a
mutation consisted of two brothers with hypogammag-
lobulinemia, only one of whom was reported to have
decreased numbers of B cells. Fresh blood samples from
these individuals were not available to confirm the di-
agnosis of XLA by immunofluorescence staining of B
cells or to evaluate Btk cDNA or protein. These patients
may not have XLA. In the other family, the patient had
a maternal uncle who died, in early childhood, of in-
fection. This patient had a markedly reduced number of
B cells that expressed an immature phenotype, as is char-
acteristic of XLA (Conley 1985). In addition, Btk protein
could not be detected in his peripheral blood mononu-
clear cells by western blot analysis. However, we have
not yet been able to identify a mutation in Btk in genomic
DNA or cDNA or by Southern blot analysis.
We identified mutations in Btk in 56 of the 61 families
with presumed sporadic XLA. In two of the remaining
five families, we have shown that the affected males in-
herited autosomal recessive defects in other genes re-
quired for normal B cell differentiation, the m heavy
chain gene (Yel et al. 1996) (MIM 147020) or the l5/
14.1 surrogate light chain gene (Minegishi et al. 1998).
Both of these patients were compound heterozygotes,
and there were no clinical features that would distinguish
them from patients with typical XLA. An Epstein-Barr
virus–transformed cell line from a third patient had nor-
mal Btk cDNA by SSCP, normal Btk message by north-
ern blot, and normal Btk protein by western blot. There-
fore, it is unlikely that this patient had X-linked
agammaglobulinemia.
The last two families in whom we did not find mu-
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Figure 1 SSCP analysis showing mutations in Btk exon 14 in patient 1426 (left), in exon 2 in patient 0310 (center), and in exon 3 in
patient 0500 (right). In each panel DNA from controls (lanes 1 and 5) is compared to the DNA from the patient (lane 2), to a mixture of DNA
from the same patient and DNA from a control (lane 3), and to DNA from the patient’s mother (lane 4).
tations in Btk were among five families with sporadic
disease in whom a proband was not available for anal-
ysis; therefore, DNA from the mother (four families) or
daughter (one family) of the affected male was analyzed.
Mutations in Btk were found in two of the mothers and
in the daughter of an affected patient (patient 0420).
The mutation in patient 0420, an arginine to cysteine
substitution at codon 28, is of particular interest because
it is the same mutation found in xid mice, a strain of
mice with a relatively mild defect in B cell development
(Wicker and Scher 1986). Although patients with mu-
tations in codon 28 have been reported (de Weers et al.
1994; Ohta et al. 1994; Zhu et al. 1994; Hashimoto et
al. 1996; Vorechovsky et al. 1997), these mutations have
been arginine to histidine or arginine to proline substi-
tutions. It had been speculated that the milder phenotype
in xid mice, compared with patients with XLA, might
be due to the R28C mutation having less severe con-
sequences than other mutations in Btk (Rawlings and
Witte 1994; Smith et al. 1994); however, more recent
studies indicate that mice that express no Btk have a
phenotype that is similar to that of xid mice (Kerner et
al. 1995; Khan et al. 1995). The patient with the R28C
mutation died at 45 years of age, of chronic pulmonary
disease. He was presumed to have XLA, because of very
low concentrations of serum immunoglobulins and
markedly reduced numbers of B cells. However, it is
notable that he survived until middle age during the
period when most patients with XLA did not reach
adulthood.
The absence of a Btk mutation in the two other moth-
ers could be attributed to a new mutation in the maternal
gamete, failure to detect the mutation by SSCP screening,
or mutations in other genes. If we exclude the patients
in whom we were not able to confirm the marked de-
crease in B cell numbers that is characteristic of XLA,
mutations in Btk were identified in 43 of 46 patients
with presumed sporadic XLA.
DNA was available for study from 49 of the mothers
of patients with sporadic XLA and documented muta-
tions in Btk, including the mothers of the three patients
who were deceased. Southern blot analysis (5 families)
or SSCP (44 families) was used to determine whether
the mother was a carrier of the mutation. In 41 of the
families, DNA from the mother showed the abnormal
allele found in her son and the normal allele, which
indicated that she was a carrier of XLA. In the remaining
eight families, the mother’s DNA was normal by SSCP
analysis. To rule out the possibility that the abnormal
allele was not detected because of preferential amplifi-
cation of the normal versus the mutant allele, equal
mixtures of DNA from the affected son and a normal
control were analyzed by SSCP in seven of the eight
families. In each of the seven families, the mixture of
the normal and abnormal allele permitted the identifi-
cation of the abnormal allele (fig. 1). DNA was not avail-
able from the deceased father of patient 0410; however,
the fact that we were able to identify the mutant allele
in the heterozygous daughter indicated that the failure
to identify the mutant allele in the mother of the patient
could not be attributed to selective amplification of the
normal allele. These findings indicate that in 8 of 49
families, the mother of the patient was a somatic or
gonadal chimera for the new mutation, or, more likely,
the new mutation arose in the maternally derived gam-
ete. In seven of the families that included affected broth-
ers but no affected maternal cousins or uncles, DNA
samples from the mothers of the patients were studied.
In all seven families, the mother was heterozygous for
the mutation seen in her sons.
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Figure 2 Pedigree for patient 1000 is shown in A. DNA from
each individual was analyzed by PCR for the polymorphism at
DSX101 (B) and by SSCP for the mutation in exon 8 (C).
To identify the source of mutation, we evaluated all
available family members, including maternal aunts,
grandparents, and/or great-grandparents, in 20 families
in which the mother of a patient with sporadic XLA was
a carrier of the mutation found in her son. Genomic
DNA was screened by SSCP for the mutation found in
the proband, and linkage analysis, using the highly poly-
morphic short tandem repeats at DXS6799, DXS6797,
DXS178, DXS101, and DXS6804, was performed, to
determine the haplotype bearing the mutation. In five of
these families, the maternal grandmother was a carrier
of the mutation found in her grandson. In 15 families,
neither of the maternal grandparents was a carrier of
the mutation, and the mutation occurred on the grand-
paternal haplotype (fig. 2). In one of the families in
which the maternal grandmother was a carrier of XLA
and in four additional families that included more than
one affected male, we were able to demonstrate that the
mutation occurred on the maternal grandpaternal or
great-grandpaternal allele.
In previous studies, we identified a family in which a
healthy father transmitted the XLA defect to two of his
daughters, indicating gonadal or somatic chimerism (pa-
tient 2500) (Parolini et al. 1993). To assess the frequency
of this event, we evaluated 11 sisters of seven women
who were carriers of XLA and whose mutation occurred
on the paternal haplotype. None of the 11 sisters were
carriers of the mutations seen in their nephews.
Studies evaluating the source of a new mutation in
other genetic disorders have suggested that certain types
of mutations may be more likely to occur in male gam-
etes than in female gametes; therefore, we examined the
specific mutations in Btk that originated in paternal ver-
sus maternal gametes. As shown in table 1, 13 of 20
mutations derived from paternal gametes were sin-
gle–base-pair substitutions, 5 were small deletions, 1 was
a 3-bp deletion accompanied by a 5-bp insertion, and
the last was a large insertion. By contrast, three of eight
mutationsderived from maternal gametes were sin-
gle–base-pair substitutions, three were small deletions,
one was a 16-bp deletion accompanied by a 4-bp
insertion, and one was a single–base-pair insertion (table
1).
Discussion
This study indicates that mutations in Btk can be
found in ∼90%–95% of males with sporadic immu-
nodeficiency characterized by early onset of infections,
hypogammaglobulinemia, and !1% B cells. The vast
majority of the mutations in these patients and in pa-
tients with a family history of antibody deficiency could
be detected by SSCP screening of genomic DNA. Mu-
tations that could be identified only by cDNA analysis
or Southern blotting did occur and have been reported
in other series (Jin et al. 1995), but in our study, these
constituted only 3% of the total mutations.
In 7 of 101 families, a mutation in Btk was not iden-
tified. Mutations in other genes required for B cell de-
velopment were identified in two patients who were clin-
ically indistinguishable from patients with typical XLA.
Fresh blood samples that could be used for lymphocyte
analysis and to provide cDNA or protein were not avail-
able from affected males in four families in whom we
did not identify mutations in Btk, which made it difficult
to determine whether these patients had findings typical
of XLA. Strong evidence for the diagnosis of XLA was
found in only one patient in whom a mutation in Btk
was not detected. This patient may have a mutation that
affects either Btk transcription or the splicing of the Btk
message in a region of the gene that was not examined.
Past studies have indicated that ∼10% of patients with
the clinical and laboratory characteristics of XLA are
females (McKinney et al. 1987; Conley and Sweinberg
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1992) and have suggested that an equal proportion of
males with the same phenotype might have disorders
that were etiologically unrelated to XLA (Conley and
Sweinberg 1992). The percentage of males in this study
without mutations in Btk fits well with this estimate. We
continue to analyze DNA from several females with a
disease phenotypically similar to XLA, in whom the ge-
netic etiology of the disease remains unclear, suggesting
that there are additional genes, combinations of genes,
or environmental factors that can result in an XLA-like
phenotype.
The distribution of mutations in Btk reported in this
study is similar to that recorded in a database of Btk
mutations contributed by many laboratories (Vihinen et
al. 1996). However, it has not been possible to determine
whether all of the mutations in that registry were in-
dependently derived, as some families may have been
studied by more than one institution. All but 1 of the
94 mutations identified in this study represented inde-
pendent mutational events. The high incidence of in-
dependently derived mutations in our series contrasts
with the findings in another potentially lethal X-linked
disorder, hemophilia B, in which 25% of patients in the
United States have mutations that can be attributed to
three founders (Ketterling et al. 1991). It has been pos-
tulated that these three mutations result in a milder form
of hemophilia and are thus maintained in the population
(Ketterling et al. 1991). The absence of similar, shared
mutations in Btk suggests that a mild form of XLA,
consistent with survival in a preantibiotic era, is uncom-
mon or nonexistent.
In a family with a sporadic case of an X-linked disease,
the probability that the mother of the patient is a carrier
of that disease is influenced by the source of new mu-
tations. If most new mutations occur in male gametes,
as is seen in several autosomal dominant as well as X-
linked disorders (Stephens et al. 1992; Goldberg et al.
1993; Palau et al. 1993; Carlson et al. 1994; Rossiter
et al. 1994; Tuchman et al. 1995; Becker et al. 1996;
Lazaro et al. 1996), the mother would almost always be
a carrier. The observation that most new mutations are
of paternal origin has in some cases been attributed to
the fact that spermatogenesis is associated with a 10-
fold higher number of cell divisions compared with oo-
genesis (Carlson et al. 1994); however, the source of new
mutations may be affected by the type of mutation.
Duchenne muscular dystrophy is caused by deletions in
the dystrophin gene in 60%–70% of patients; 60% of
these deletions originate in female gemetes (van Essen
et al. 1992). In hemophilia A, 35%–50% of mutations
are due to large intragenetic inversions that disrupt the
sequence between exon 22 and exon 23. These inver-
sions are derived almost exclusively from male gametes
(Rossiter et al. 1994; Becker et al. 1996). Charcot-Marie-
Tooth disease is usually caused by a 1.5-Mb duplication
on chromosome 17p11.2 (Lupski et al. 1991). This mu-
tation also almost always originates in a male gamete
(Palau et al. 1993).
Of the 49 mothers of patients with sporadic XLA and
proven mutations in Btk in our series, 84% were carriers
of the mutation found in their sons. This is similar to
the percentage of mothers of patients with sporadic he-
mophilia A, hemophilia B, or X-linked severe combined
immunodeficiency, who are carriers of the mutations
found in their sons (Knobloch et al. 1993; Becker et al.
1996; Puck et al. 1997). In the series reported here, the
proportion of mutations originating in male gametes
that were point mutations (13 [66%] of 20) was similar
to the proportion of point mutations in the entire group
of independently occurring mutations (62 [69%] of 93).
By contrast, three of eight of the mutations occurring in
female germ cells were point mutations, and there was
a slight enrichment for small deletions and/or insertions
in this group of mutations. In three of the eight cases in
which the maternal gamete was the source of the mu-
tation, linkage analysis demonstrated that the mutant X
chromosome was the paternally derived X. The source
of the mutant X chromosome could not be determined
in the other families.
In the absence of mutation detection, this study allows
a physician or genetic counselor to predict the repro-
ductive risk of the parents, sisters, and maternal aunts
of males with sporadic defects in B cell development.
Both parents have a small but appreciable (3%–5%) risk
of being carriers of rare autosomal recessive defects in
B cell development. The risk that the mother of the pa-
tient is a carrier of XLA can be calculated on the basis
of the percentage of males with mutations in Btk (92%)
times the percentage of mothers who carry the mutation
found in their son (84%), or ∼77%. This is an approx-
imation because, although this study did not identify any
women who were gonadal chimeras, in other similar
disorders—for example, X-linked severe combined im-
munodeficiency—maternal gonadal chimeras have been
reported (Puck et al. 1995). This rare event would
slightly increase the predicted risk to the mother. The
risk to the sister of the affected male is half the risk to
the mother (38%). The risk that a maternal aunt is a
carrier of XLA can be estimated on the basis of the
observation that the maternal grandmother was a carrier
of the mutation found in her grandson in 5 (16%) of
30 families available for analysis. Even when coupled
with the small risk that either of the patient’s maternal
grandparents might be a gonadal chimera, the proba-
bility that the maternal aunt is a carrier of XLA is !10%.
These figures, based on a relatively large number of fam-
ilies presumed to have XLA, should facilitate genetic
counseling in families with sporadic disease.
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Table 1
Mutations in Btk in Patients with X-Linked Agammaglobulinemia





0015*f ) Intron 1 5′ untranslated G r A Splice-donor defect (1) S )
0025 ) Intron 1 5′ untranslated T r G Regulatory defect (6) S )
0030 ) Intron 1 5′ untranslated T r G Regulatory defect (6) C, U, EG )
0060* ) ) ) Insertion (13 kb) within
intron 1
Frameshift B )
0100 1 Exon 2 PH ATG r GTG No start S )
0200 13 Exon 2 PH CGA r TGA Arg r Stop U )
0300 13 Exon 2 PH CGA r TGA Arg r Stop B )
0310 13 Exon 2 PH CGA r TGA Arg r Stop S Mother (M)
0400 15 Exon 2 PH CAA r TAA Gln r Stop U )
0410* 21 Exon 2 PH TCA r TAA Ser r Stop S )
0420* 28 Exon 2 PH CGC r TGC Arg r Cys S Mother (M)
0450 40 Exon 2 PH TAT r TGT Tyr r Cys S MGF (P)
0470 62 Exon 3 PH A del Frameshift B, U, EG )
0480 71 Exon 3 PH A del (7 As) Frameshift B )
0500 76, 77 Exon 3 PH GAAA del Frameshift S Mother (M)
0507* 77, 78 Exon 3 PH GACA del Frameshift S )
0520* 80 Exon 3 PH CCG r CCA Splice-donor defect (1) S MGGF (P)
0540* ) ) ) Insertion (130 kb) within
intron 4
No transcript S MGF (P)
0590* 112 Exon 5 PH TAC r TAA Tyr r Stop S )
0600 113 Exon 5 PH GTC r GAC Val r Asp S )
0620 114, 115 Exon 5 PH TCT del Phe deletion S )
0621 115 Exon 5 PH TCC r TTC Ser r Phe S MGF (P)
0630* 117 Exon 5 PH ACT r CCT Thr r Pro S )
0700 130 Exon 5 PH A del (5 As) Frameshift B )
0703* ) ) ) Deletion (130 kb) of ex-
ons 6–19
) S )
0710 (131) Intron 5 PH A r G Splice acceptor (2) S )
0730 145 Exon 6 TH TGC r TGA Cys r Stop C, EG )
0770 166 Exon 6 TH CAA r TAA Gln r Stop U )
0771 166 Exon 6 TH CAA r TAA Gln r Stop U, C )
0780* (174) Intron 6 TH G r A Splice acceptor (1) S )
0800 186 Exon 7 Proline rich A ins (6 As) Frameshift S Mother (P)
0810 187, 188 Exon 7 Proline rich TCTT del Frameshift U MGGF (P)
0820* 189 Exon 7 Proline rich C del (5 Cs) Frameshift S Mother (M)
0850* ) ) ) Deletion (2.6 kb) of ex-
ons 8–10
Frameshift B, EG )
0870* 203, 204 Exon 8 Proline rich CGC del and TGGTG ins Frameshift S MGF (P)
0900 218 Exon 8 Proline rich A del (5 As) Frameshift B )
0940* 239 Exon 8 SH3 G del Frameshift S )
0980 244 Exon 8 SH3 TTG r TAG Leu r Stop B MGF (P)
1000 252 Exon 8 SH3 TGG r TAG Trp r Stop S MGF (P)
1030 255 Exon 8 SH3 CGA r TGA Arg r Stop S )
1031 255 Exon 8 SH3 CGA r TGA Arg r Stop U )
1070* (259) Intron 8 SH3 T r C Splice-donor defect (2) C, EG )
1100 261 Exon 9 SH3 G del TTA ins Frameshift S )
1107* (280) ) ) 500-bp ins starting at 5
position of splice-donor
site of intron 9
) S )
1110* 288 Exon 10 SH2 CGG r CAG Arg r Gln S )
1111† 288 Exon 10 SH2 CGG r CAG Arg r Gln S )
1120 (298) Intron 10 SH2 G del, 11-bp ins Splice-acceptor defect (9) C, EG )
1130 (298) Intron 10 SH2 A deletion Splice-acceptor defect (2) U )
1131 (298) Intron 10 SH2 A r C Splice-acceptor defect (2) B )
1133 (298) Intron 10 SH2 G r A Splice-acceptor defect (1) U )
1150 302 Exon 11 SH2 GGA r GAA Gly r Glu S MGF (P)
1160* 307 Exon 11 SH2 AGA r ACA Arg r Thr S MGF (P)
(continued)
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1180 315 Exon 11 SH2 TAT r TAG Tyr r Stop S )
1200 325 Exon 11 SH2 G del (4 Gs) Splice defect S MGF (P)
1210* 326–330 Exon 12 SH2 ACCCTCAAGGGGT
del
Frameshift S MGF (P)
1250* 348 Exon 12 SH2 GAG r TAG Glu r Stop U )
1300 361 Exon 12 SH2 TAC r TGC Tyr r Cys B, EG )
1400 375 Exon 13 SH2 TAT r TAG Tyr r Stop S MGF (P)
1420* 391 Exon 13 Kinase A r G Creates cryptic splice
site
C )
1426* 404 Exon 14 Kinase TTC del Phe del S Mother (M)
1427† 404 Exon 14 Kinase TTC del Phe del S )
1440 430 Exon 14 Kinase AAG r AGG Lys r Arg S )
1445* 445 Exon 14 Kinase GAA r GAC Glu r Asp B )
1450* 460 Exon 15 Kinase TTG r TAG Leu r Stop S )
1470 509 Exon 15 Kinase ATG r ATA Met r Ile S MGF (P)
1471 509 Exon 15 Kinase ATG r ATA Met r Ile S )
1500 520 Exon 15 Kinase CGA r CAA Arg r Gln B MGF (P)
1600 520 Exon 15 Kinase CGA r CAA Arg r Gln U, C, EG )
1700 520 Exon 15 Kinase CGA r TGA Arg r Stop S MGF (P)
1720 (522) Intron 15 Kinase TTTG del Splice-acceptor defect
(9–12)
B )
1750* 525 Exon 16 Kinase CGA r GGA Arg r Gly S Mother (M)
1800 527, 528 Exon 16 Kinase TTTG del Frameshift S MGF (P)
1830* 533 Exon 16 Kinase G del (2 Gs) Frameshift S )
1850* 535 Exon 16 Kinase GTT r TTT Val r Phe; C )
1900 542 Exon 16 Kinase CTG r CCG Leu r Pro U )
2000 (544) Intron 16 Kinase G r T Splice-donor defect (1) B )
2017 (544) Intron 16 Kinase G r T Splice-donor defect (1) S )
2100 562 Exon 17 Kinase CGG r TGG Arg r Trp C )
2110* 563 Exon 17 Kinase TGG r TTG Trp r Leu C, U )
2116* 566 Exon 17 Kinase G del (2Gs) Frameshift S MGF (P)
2200 581 Exon 17 Kinase TGG r CGG Trp r Arg S )
2210 582 Exon 17 Kinase GCT r GTT Ala r Val U )
2220 584 Exon 17 Kinase G r A Splice-donor defect (1) C )
2270* 588 Exon 18 Kinase TGG r TAG Trp r Stop S )
2273† 588 Exon 18 Kinase TGG r TAG Trp r Stop U MGGF (P)
2280 589 Exon 18 Kinase GAA r GAT Glu r Asp S )
2300 591 Exon 18 Kinase TAC r TAA Tyr r Stop S )
2320* 594 Exon 18 Kinase GGG r GAG Gly r Glu S )
2370 622 Exon 18 Kinase GCT r CCT Ala r Pro, S )
2390* 629–634 Exon 18 Kinase 16-bp del and 4-bp ins ) S Mother (M)
2400 630 Exon 18 Kinase ATG r AAG Met r Lys C )
2430* ) ) ) Deletion (7.5 kb) of
exon 19
Incomplete protein S )
2433* ) ) ) Deletion (12 kb) of
exon 19
Incomplete protein S )
2500 652 Exon 19 Kinase CTA r CCA Leu r Pro B, C MGGF (P)
a For mutations that occur in introns, the codon at the splice site is noted in parentheses.
b If an insertion (ins) or deletion (del) occurs in a run of repeated base pairs, the number of base pairs is indicated in parentheses.
c The position of splice defects is indicated as a minus sign () if the defect is 5′ to the splice site and as a plus sign () if the defect is 3′
to the splice site.
d S  sporadic; B  brothers; U  uncles; C  cousins; and EG  earlier generations.
e MGF  maternal grandfather; MGGF  maternal great-grandfather; M  mutations that are assumed to have originated in maternal germ
cells; and P  mutations that are assumed to have originated from paternal germ cells.
f An asterisk (*) indicates that the mutation found in this patient has not been previously described. If a new mutation occurred in more
than one patient, the second patient is indicated by a dagger (†).
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